Precision Medicine Track Day Two

 

Precision 2018 Day 2

08:00 Registration opens

Opening keynotes: Precision medicine stories

08:55

Chair's opening remarks

09:00

Precision medicine stories from inside

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Paul Peter Tak
09:25

Towards prevention of autoimmune disease: the example of rheumatoid arthritis

  • Predictors for rheumatoid arthritis (RA) development will be presented
  • PRAIRI study is the first evaluating the effects of a biopharmaceutical in subjects at risk of developing RA
  • A single infusion of 1000 mg rituximab delays the development of arthritis up to 12 months
Kari Stefansson
09:50

From discovery genetics to precision medicine

10:15

Reserved for supporting partner

Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details

10:40 Networking Break

round tables
11:40

Roundtable discussion session

This roundtable session will run as two, 30 minute rotations, enabling you to join 2 roundtables of your choice
  • Table 1: Health economics meets real world data
  • Table 2: Ethics to consider when discussing precision medicine
  • Jeffrey Skopek

    Jeffrey Skopek, Lecturer in Medical Law, Ethics, and Policy, University of Cambridge

  • Table 4: Cost and benefits of precision medicine
  • Alastair Kent OBE

    Alastair Kent OBE, Ambassador, Genetic Alliance U.K.

  • Table 5: Implementing precision medicine in healthcare systems
  • Table 6: Diagnostics – where precision medicine will take us
  • Table 7: Whole body screening – the future of healthcare
  • Table 8: Precision medicine for infectious disease
  • 12:40

    Speed Networking

    A fun, exciting and effective way to make a lot of initial connections (in a very different environment from the standard business networking meetings)
    Panel discussion
    13:00

    13:00 Networking Lunch

    Break out panel: Patient involvement in precision medicine
    • What are the benefits of involving the public in precision medicine
    • The patient experience with precision medicine and patient involvement
    • How clinicians can improve the patient experience
    • What are the barriers to involvement and how can they be overcome

    Drug development

    Precision Medicine - Oncology

    Precision Medicine - Oncology

    Chaired by TBC

    Precision Medicine - Oncology
    14:30

    Mendelian genomics and precision medicine efforts at Yale

    • Biomarker discovery for Mendelian and Cancer Genomics
    • Precision Medicine initiative/efforts at Yale
    • Present PM cases of liver and brain cancer
    • Impact of new and upcoming technologies on PM
    Precision Medicine - Oncology
    14:50

    The Human Protein Atlas - implications for human biology and precision medicine

    • Knowledge of the spatial distribution of proteins is essential to understand human biology in health and disease
    • The Human Protein Atlas constitutes an open-access knowledge-based resource, focusing on an integrated omics approach for in situ detection of human proteins down to the single cell level
    • All human protein coding genes have been classified using a combination of genomics, transcriptomics, proteomics and antibody-based profiling, and used for studying global protein expression patterns
    Drug Development
    15:10

    The evolution of Pharmacogenetics (PGx) as a tool to support drug development

    • What have we learned about PGx over the last 10 years
    • How best can we utilise this to support drug development going forward
    • The utility of clinical trials and PGx to support target validation
    Precision Medicine - Oncology
    15:10

    Genomic medicine implementation

    Reserved for supporting partner
    Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
    Drug Development
    15:30

    Implementing precision medicines: what are the challenges?

    • Sharing of case-studies/examples on challenges and solutions in precision medicine development through to integration in treatment pathways, including;
    • Biomarker discovery
    • Clinical trial design and delivery
    • Drug-diagnostic co-development
    • Precision Medicine launch and delivery to the patient
    Precision Medicine - Oncology
    15:30

    Precision medicine in oncology: what is it exactly and where are we?

    • A better understanding of cancer biology has opened the door of precision medicine in oncology
    • The identification of specific molecular alterations in some tumour types has translated into major therapeutic achievements
    • High throughput technologies have allowed the elaboration of prognostic signatures that led to treatment de-intensification in breast cancer
    • However, it has not been demonstrated to date that the use of high throughput technologies to guide therapy improved patients’ outcomes
    Vivienne Parry
    15:50

    15:50 Networking break

    Breakout Panel: Inside the ethics committee – the ethics behind using precision medicine
    • Panel exploring the various ethical implications surrounding precision medicine
    • Big data and patient data usage
    • Best practice for ethical decisions

    Precision Medicine - Rare Disease

    Healthcare Track

    Drug development

    Healthcare Track

    Chaired by TBC

    Drug Development
    16:30

    Major public-private biomedical research partnership managed by the Foundation for the National Institute of Health

    Reserved for supporting partner
    Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
    Precision Medicine - Rare Disease
    16:30

    Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours

    • There is a need for new methods able to better discriminate between sensitive and resistant tumours to a given cancer treatment from the genomic profiles of these tumours
    • Combining multiple gene mutations via machine learning results in better discrimination than that provided by the best single-gene marker in about half of the 127 analysed drugs
    • Importantly, the proportion of sensitive cell lines that are correctly predicted as sensitive (recall) of the single-gene marker was lower than that of the multi-gene marker in 93% of the drugs
    Healthcare Track
    16:30

    What does good care feel like? A patient's perspective

    • What do we mean by precision medicine? 
    • Expectations, fears and hope
    • Precision - in care, treatment and communication
    Drug Development
    16:50

    Genomic scale drug design

    • First time in history we can have full genome binding affinity for molecules
    • This will shift the industry to a different design process, less risky, more precise
    • Opening of the single genome drug optimisation
    Healthcare Track
    16:50

    Cancer susceptibility – screening and prevention using genomics

    Reserved for supporting partner
    Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
    Drug Development
    17:10

    Analytical tools to help with drug development

    Reserved for supporting partner
    Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
    Precision Medicine - Rare Disease
    17:10

    Need for patient registries for rare disease clinical trials and how to integrate them into the EMR

    • Hear how Sanford Research built a registry for batten disease and how they are expanding it and implementing it into electronic health records
    • What do these registries mean for clinical trials in the rare disease field?
    • How do approaches to registries and electronic health systems differ globally?
    Healthcare Track
    17:10

    Actionable genes

    • The payer perspective of the genetic testing market
    • What our customers want
    • Actionable and teiring of genes
    • Commissioning of genetic tests
    Drug Development
    17:30

    Academic built compounds (ABC) – with the move to drug discovery platforms are we forgetting our ABCs?

    • An overview of the Oncology drug development landscape - comparing approaches and exhibiting the successes from Academia
    • MicroQuin is offering a novel approach and first-in-class treatment to ALL Breast Cancers.  This will spotlight MicroQuin’s efforts and explain why this can’t be found using a platform approach
    • Examining the Oncology pipeline: The next generation drugs and why ABC is still unbeatable
    Precision Medicine - Rare Disease
    17:30

    Induced pluripotent stem cells as a workhorse for human genetic studies

    • Learn how human iPS cells are transforming the study of disease alleles
    • What are the opportunities and challenges in using iPSCs as disease models?
    • Introduction to the Human Induced Pluripotent Stem Cells Initiative (HipSci)
    Healthcare Track
    17:30

    Migrating Breast Health screening from imaging to metabolic detection via Wearable technology and Artificial Intelligence for the mass population

    • Hospital based breast cancer detection serves only a small percentage of the total population due to physician access or the woman’s lack of interest in being screened via mammographic interpretation
    • wearable technology that accurately detects breast cancer through tracking metabolic changes as a woman navigates through her normal daily routine
    • Dense tissue affects over 50% of the female population leading to an earlier onset of cancer and over 70% of biopsy’s occurring on non-cancerous tissue

    17:50 End of day 2: Poster viewing and networking drinks reception

    last published: 15/Dec/17 11:05 GMT

     

     

    The World Precision Medicine Congress is both a world-class conference, bringing together hundreds of pharma, biotech and academic leaders from around the globe, and a fantastic exhibition showcasing the newest technologies, developments and solutions. There is a registration fee to attend the congress, however the exhibition is absolutely free to attend 

    CONTACT US 
    phone: +44 (0)207 092 1134 
    email: 
      
    joan.shutt@terrapinn.com